These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 9579701)
1. Cholecystokinin, beta-endorphin and vasoactive intestinal peptide in peripheral blood mononuclear cells of drug-naive schizophrenic patients treated with haloperidol compared to healthy controls. Mauri MC; Rudelli R; Vanni S; Panza G; Sicaro A; Audisio D; Sacerdote P; Panerai AE Psychiatry Res; 1998 Mar; 78(1-2):45-50. PubMed ID: 9579701 [TBL] [Abstract][Full Text] [Related]
2. Beta-endorphin, vasoactive intestinal peptide and cholecystokinin in peripheral blood mononuclear cells from healthy subjects and from drug-free and haloperidol-treated schizophrenic patients. Panza G; Monzani E; Sacerdote P; Penati G; Panerai AE Acta Psychiatr Scand; 1992 Mar; 85(3):207-10. PubMed ID: 1561892 [TBL] [Abstract][Full Text] [Related]
3. The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial. Zhang XY; Zhou DF; Cao LY; Wu GY Psychopharmacology (Berl); 2006 Sep; 188(1):12-7. PubMed ID: 16906395 [TBL] [Abstract][Full Text] [Related]
4. Brain and gut neuropeptides in peripheral blood mononuclear cells. Panerai AE; Sacerdote P J Physiol Paris; 1993; 87(5):283-9. PubMed ID: 8298605 [TBL] [Abstract][Full Text] [Related]
5. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Kim YK; Kim L; Lee MS Schizophr Res; 2000 Sep; 44(3):165-75. PubMed ID: 10962218 [TBL] [Abstract][Full Text] [Related]
6. The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. Arango C; Breier A; McMahon R; Carpenter WT; Buchanan RW Am J Psychiatry; 2003 Aug; 160(8):1421-7. PubMed ID: 12900303 [TBL] [Abstract][Full Text] [Related]
7. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Artaloytia JF; Arango C; Lahti A; Sanz J; Pascual A; Cubero P; Prieto D; Palomo T Am J Psychiatry; 2006 Mar; 163(3):488-93. PubMed ID: 16513871 [TBL] [Abstract][Full Text] [Related]
8. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Tollefson GD; Sanger TM Am J Psychiatry; 1997 Apr; 154(4):466-74. PubMed ID: 9090332 [TBL] [Abstract][Full Text] [Related]
9. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study. Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987 [TBL] [Abstract][Full Text] [Related]
10. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Arvanitis LA; Miller BG Biol Psychiatry; 1997 Aug; 42(4):233-46. PubMed ID: 9270900 [TBL] [Abstract][Full Text] [Related]
11. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317 [TBL] [Abstract][Full Text] [Related]
12. Clinical study of cerebrospinal fluid neuropeptides in patients with primary trigeminal neuralgia. Qin ZL; Yang LQ; Li N; Yue JN; Wu BS; Tang YZ; Guo YN; Lai GH; Ni JX Clin Neurol Neurosurg; 2016 Apr; 143():111-5. PubMed ID: 26918582 [TBL] [Abstract][Full Text] [Related]
13. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial. Gomez JC; Crawford AM J Clin Psychiatry; 2001; 62 Suppl 2():6-11. PubMed ID: 11232753 [TBL] [Abstract][Full Text] [Related]
14. Reduced neuronal expression of insulin-degrading enzyme in the dorsolateral prefrontal cortex of patients with haloperidol-treated, chronic schizophrenia. Bernstein HG; Ernst T; Lendeckel U; Bukowska A; Ansorge S; Stauch R; Have ST; Steiner J; Dobrowolny H; Bogerts B J Psychiatr Res; 2009 Sep; 43(13):1095-105. PubMed ID: 19394958 [TBL] [Abstract][Full Text] [Related]
15. Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia. Rémillard S; Pourcher E; Cohen H J Int Neuropsychol Soc; 2008 Jan; 14(1):110-8. PubMed ID: 18078537 [TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Breier A; Hamilton SH Biol Psychiatry; 1999 Feb; 45(4):403-11. PubMed ID: 10071708 [TBL] [Abstract][Full Text] [Related]
17. Concentration of cholecystokinin in cerebrospinal fluid is decreased in psychosis: relationship to symptoms and drug response. Beinfeld MC; Garver DL Prog Neuropsychopharmacol Biol Psychiatry; 1991; 15(5):601-9. PubMed ID: 1956989 [TBL] [Abstract][Full Text] [Related]
18. Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients. Casademont J; Garrabou G; Miró O; López S; Pons A; Bernardo M; Cardellach F J Clin Psychopharmacol; 2007 Jun; 27(3):284-8. PubMed ID: 17502776 [TBL] [Abstract][Full Text] [Related]
19. Dopamine receptor responsivity in schizophrenic patients before and after switch from haloperidol to risperidone. Markianos M; Hatzimanolis J; Lykouras L Psychiatry Res; 1999 Dec; 89(2):115-22. PubMed ID: 10646830 [TBL] [Abstract][Full Text] [Related]
20. Effects of haloperidol and risperidone on cerebrohemodynamics in drug-naive schizophrenic patients. Lee SM; Chou YH; Li MH; Wan FJ; Yen MH J Psychiatr Res; 2008 Mar; 42(4):328-35. PubMed ID: 17412363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]